Year: 2019

Chicken Soup for the Soul Entertainment Announces Timing of Regular Monthly Dividend for December 2019 for Series A Cumulative Redeemable Perpetual Preferred Stock

Written by Customer Service on November 18, 2019. Posted in Dividend Reports And Estimates.

COS COB, Conn., Nov. 18, 2019 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment Inc. (“CSS Entertainment”) (Nasdaq: CSSE, CSSEP), a growing media company building online video on-demand (“VOD”) networks that provide video content for all screens, today announced the timing for the payment of its declared regular monthly dividend of $0.2031 per share of its 9.75% Series A Cumulative Redeemable Perpetual Preferred Stock for December 2019. The dividend will be payable on December 16, 2019 to holders of record as of November 30, 2019. The dividend will be paid in cash.ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENTChicken Soup for the Soul Entertainment Inc. is a growing media company building and acquiring streaming VOD networks that provide content for all screens. CSS Entertainment has a majority stake in Crackle Plus, a joint...

Spectrum Global Solutions Announces Closing of WaveTech GmbH Acquisition

Written by Customer Service on November 18, 2019. Posted in Mergers And Acquisitions.

Patented Battery Health Technology to be Sold into Spectrum’s Established Tier-1 Customer BaseLONGWOOD, FL, Nov. 18, 2019 (GLOBE NEWSWIRE) — Spectrum Global Solutions, Inc. (the “Company” or “Spectrum”) (OTCQB: SGSI), a leading single-source provider of next-generation communications network infrastructure and maintenance solutions, today announced the closing of the previously announced acquisition of WaveTech GmbH (“WT” or “WaveTech”), a German global technology company focused on next generation energy management and extension, data analytics and monitoring services extending the useful life of battery systems, which is currently working with a Fortune 1000 client base.WaveTech’s patented Crystal Control Technology (CCT®), the product of over a decade of R&D efforts in Norway and Germany, prevents...

Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

Written by Customer Service on November 18, 2019. Posted in Public Companies.

HAMPTON, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells. In certain inflammatory diseases, such as chronic idiopathic urticaria (CIU), also known as chronic spontaneous urticaria (CSU), mast cell degranulation plays a central role in the onset and progression of the disease. Following completion of the study in healthy volunteers, Celldex plans to further study CDX-0159 in CIU.“CDX-0159 is a potent KIT inhibitor that we believe has significant potential in diseases driven by mast cells via KIT,” said Diane...

ECMOHO to Report Third Quarter 2019 Unaudited Financial Results on November 25, 2019

Written by Customer Service on November 18, 2019. Posted in Public Companies.

SHANGHAI, China, Nov. 18, 2019 (GLOBE NEWSWIRE) — ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the rapidly growing non-medical health and wellness market in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2019, after U.S. markets close on Monday, November 25, 2019.ECMOHO’s management will host an earnings conference call at 8:00 PM U.S. Eastern Time on Monday, November 25, 2019 (Tuesday, November 26 at 9:00 AM Beijing/Hong Kong Time).Dial-in numbers for the live conference call are as follows:International: +65-6713-5090Mainland China: 400-620-8038United States: +1-845-675-0437Hong Kong: +852-3018-6771Passcode: 1268757A telephone replay of the call will be available after the conclusion...

Notification of Major Holdings

Written by Customer Service on November 18, 2019. Posted in Public Companies.

TR-1: Standard form for notification of major holdingsSection 9 Attachment

Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Written by Customer Service on November 18, 2019. Posted in Public Companies.

Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutationStable background use of CFTR therapies was permittedMilestone advances Corbus’ vision to pioneer the development of transformative medicines that target the endocannabinoid systemNorwood, MA, Nov. 18, 2019 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of patient enrollment in the Phase 2b study evaluating the efficacy and safety of lenabasum for the treatment of cystic fibrosis (CF). The Company expects to report topline data from this...

CooperCompanies Announces CooperVision Has Received FDA Approval of MiSight® for the Treatment of Myopia in Children

Written by Customer Service on November 18, 2019. Posted in Public Companies.

SAN RAMON, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) — CooperCompanies (NYSE: COO), announced today that CooperVision has received U.S. Food and Drug Administration (FDA) approval of its MiSight® 1 day contact lens1, indicated to slow the progression of myopia (nearsightedness or short-sightedness) when initially prescribed for children 8-12 years old. MiSight® 1 day has been scientifically proven to reduce myopic progression by up to 59%2. This is the first FDA approved myopia management contact lens and is expected to be available in the U.S. beginning in March of 2020. “MiSight is a revolutionary product that can make a meaningful difference in the lives of children needing visual correction,” said President and CEO Al White. “Today’s approval is a big step forward for the ophthalmic industry as eye care professionals finally...

Pillar Marketing Group, Inc., Announces Acquisition Purchase of Controlling interest in Select-TV Solutions, Inc., Changing their name to BioQuest Corp. and Appoints Thomas Hemingway as Chairman and CEO.

Written by Customer Service on November 18, 2019. Posted in Public Companies.

Newport Beach, Nov. 18, 2019 (GLOBE NEWSWIRE) — BioQuest Corp, (BQST or the “COMPANY”) (OTC:BQST), (the temporary symbol on 11/15/2019 is SELTD. Please note that a “D” has been appended as the 5th character for 20 business days including the effective date. After 20 business days the new symbol will be BQST). a provider of High-End CBD products to the retail, direct and internet markets, announced today that it has purchased controlling interest in SELT and appoints Thomas Hemingway as Chairman and CEO.BioQuest, Corporation – markets, packages and distributes an assortment of Hemp-CBD based products for the health-conscious consumer. Our mission is to Create High End, Products and bring together all relevant CBD content in the Nutraceutical and Pharmaceutical markets, to one place so that it is easily found and comparable by...

GTX Corp Reports Third Quarter 2019 Financial Results and Corporate Summary Update

Written by Customer Service on November 18, 2019. Posted in Public Companies.

LOS ANGELES, CALIFORNIA, Nov. 18, 2019 (GLOBE NEWSWIRE) — GTX Corp (OTCQB: GTXO) (“the Company”), a pioneer in the field of wearable GPS, people and asset tracking Location-Based Services (LBS) and Real-Time Location Systems (RTLS), today announced a summary for the Third Quarter ended September 30, 2019.Third Quarter 2019 Financial Highlights:Revenues for the three months ended September 30, 2019 were approximately $340,000 compared to approximately $195,000 for the comparable period in the prior year for an increase of approximately $145,000, or 74%.Gross Profit Margin for the three months ended September 30, 2019 was 89% compared to 77% for the three months ended September 30, 2018. This increase in margin is primarily due to the increase in higher margin IP licensing, Professional Services and subscription revenue during these...

Security National Financial Corporation Reports Financial Results For the Quarter Ended September 30, 2019

Written by Customer Service on November 18, 2019. Posted in Earnings Releases And Operating Results.

SALT LAKE CITY, Nov. 18, 2019 (GLOBE NEWSWIRE) — Security National Financial Corporation (SNFC) (NASDAQ symbol “SNFCA”) announced financial results for the quarter ended September 30, 2019.For the three months ended September 30, 2019, SNFC’s pre-tax earnings increased 115.2% from $2,212,000 in 2018 to $4,760,000 in 2019, on a 12.1% increase in revenues to $75,380,000. SNFC’s pre-tax earnings for the nine months ended September 30, 2019 decreased 57% to $11,816,000 from $27,561,000 in 2018, on a 5.9% decrease in revenue.Scott M. Quist, President of the Company, said, “I am pleased with the year to date operational performance of our Company. First, I would note our momentum. We have clearly improved each quarter this year. But disregarding quarterly momentum, on a year to date basis, adjusting out investment gains,...

Year: 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals